In the published article, there was an error in Figure 2 as published. The 3-month seizure freedom rate in OXC group should be 80.7% in the original figure. The 6-month seizure freedom rate in OXC group should be 43/55. The corrected Figure 2 and its caption appear below.
FIGURE 2
In the published article, there was also an error in the text. The 6-month seizure freedom rate in OXC group should be 43/55.
A correction has been made to 3 Result, 3.2 Primary endpoint, paragraph 1. This sentence previously stated:
“In the PPS, 78.1% (50/64, 95% CI: 66.0%–87.5%) of children in the PER group and 78.2% (43/56) in the OXC group were seizure-free at 6 months.”
The corrected sentence appears below:
“In the PPS, 78.1% (50/64, 95% CI: 66.0%–87.5%) of children in the PER group and 78.2% (43/55) in the OXC group were seizure-free at 6 months.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
perampanel, oxcarbazepine, newly diagnosed focal epilepsy, monotherapy, anti-seizure medications
Citation
Yi J-Q, Huang S, Wu M-J, Ma J-H, Huang L-J, Liang S and Sun D (2023) Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy. Front. Pharmacol. 14:1295784. doi: 10.3389/fphar.2023.1295784
Received
17 September 2023
Accepted
19 September 2023
Published
29 September 2023
Volume
14 - 2023
Edited and reviewed by
Alfredo Vannacci, University of Florence, Italy
Updates
Copyright
© 2023 Yi, Huang, Wu, Ma, Huang, Liang and Sun.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Song Liang, song11963@163.com; Dan Sun, bloveriver@163.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.